Sara joined Insmed in January 2020 and is responsible for the Company’s key financial functions, including accounting, financial planning and analysis, procurement, and investor relations, in addition to its global compliance program. With more than two decades of operational and financial leadership in the life sciences industry, Sara has raised over $2 billion in the capital marketplace while establishing strong financial controls, streamlining business operations, and building high-performing teams. Prior to joining Insmed, Sara served as the Chief Financial Officer and Chief Operating Officer at OncoSec Medical and as the Chief Financial Officer at Advaxis, Inc. She also previously held positions of increasing responsibility at Eli Lilly & Company and Johnson & Johnson. Sara is a Six Sigma Black Belt and in 2016 was named CFO of the Year – Healthcare Organization and Forty under 40 by NJBiz. She holds a BS in Finance from The College of New Jersey and an M.B.A. from Rider University. Sara is a member of the board of directors of scPharmaceuticals Inc. (Nasdaq: SCPH) and Xilio Therapeutics, Inc. (Nasdaq: XLO).